Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients- 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
Abstract
Authors
A.M. Nishikawa L. Paladini A.L. Liamas C.C. Bueno O.A.C. Clark